Hepatitis C prevalence in injecting drug users in Europe, 1990–2007: impact of study recruitment setting

2012 ◽  
Vol 141 (3) ◽  
pp. 563-572 ◽  
Author(s):  
M. RONDY ◽  
L. WIESSING ◽  
S. J. HUTCHINSON ◽  
C. MATHEÏ ◽  
F. MATHIS ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Logistic Model ◽  
Drug Users ◽  
Injecting Drug Users ◽  
Study Recruitment ◽  
Hcv Prevalence ◽  
Random Intercept ◽  
Prevalence Estimates ◽  
Low Threshold ◽  
The Impact

SUMMARYMonitoring injecting drug users' (IDUs) health is challenging because IDUs form a difficult to reach population. We examined the impact of recruitment setting on hepatitis C prevalence. Individual datasets from 12 studies were merged. Predictors of HCV positivity were sought through a multilevel analysis using a mixed-effects logistic model, with study identifier as random intercept. HCV prevalence ranged from 21% to 86% across the studies. Overall, HCV prevalence was higher in IDUs recruited in drug treatment centres compared to those recruited in low-threshold settings (74% and 42%, respectively, P < 0·001). Recruitment setting remained significantly associated with HCV prevalence after adjustment for duration of injecting and recent injection (adjusted odds ratio 0·7, 95% confidence interval 0·6–0·8, P = 0·05). Recruitment setting may have an impact on HCV prevalence estimates of IDUs in Europe. Assessing the impact of mixed recruitment strategies, including respondent-driven sampling, on HCV prevalence estimates, would be valuable.

scholarly journals Spatial mapping of hepatitis C prevalence in recent injecting drug users in contact with services

2011 ◽  
Vol 140 (6) ◽  
pp. 1054-1063 ◽  
Author(s):  
R. J. HARRIS ◽  
V. D. HOPE ◽  
A. MORONGIU ◽  
M. HICKMAN ◽  
F. NCUBE ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Drug Users ◽  
Injecting Drug Users ◽  
Developed Countries ◽  
Geographical Differences ◽  
Random Effects Models ◽  
North West ◽  
Spatially Correlated ◽  
The North ◽  
Hcv Prevalence

SUMMARYIn developed countries the majority of hepatitis C virus (HCV) infections occur in injecting drug users (IDUs) with prevalence in IDUs often high, but with wide geographical differences within countries. Estimates of local prevalence are needed for planning services for IDUs, but it is not practical to conduct HCV seroprevalence surveys in all areas. In this study survey data from IDUs attending specialist services were collected in 52/149 sites in England between 2006 and 2008. Spatially correlated random-effects models were used to estimate HCV prevalence for all sites, using auxiliary data to aid prediction. Estimates ranged from 14% to 82%, with larger cities, London and the North West having the highest HCV prevalence. The methods used generated robust estimates for each area, with a well-identified spatial pattern that improved predictions. Such models may be of use in other areas of study where surveillance data are sparse.

The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence

Addiction ◽  
2011 ◽  
Vol 106 (11) ◽  
pp. 1978-1988 ◽  
Author(s):  
Katy M. E. Turner ◽  
Sharon Hutchinson ◽  
Peter Vickerman ◽  
Vivian Hope ◽  
Noel Craine ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Users ◽  
Injecting Drug Users ◽  
Substitution Therapy ◽  
Opiate Substitution Therapy ◽  
The Impact

scholarly journals Prevalence of HIV and HCV among injecting drug users in three selected WHO-EMRO countries: a meta-analysis

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Shah Jahan Shayan ◽  
Rajab Nazari ◽  
Frank Kiwanuka
Keyword(s):  
Hepatitis C ◽  
Drug Users ◽  
Web Of Science ◽  
Meta Analysis ◽  
Injecting Drug Users ◽  
Hiv Prevalence ◽  
Mortality And Morbidity ◽  
Hcv Prevalence ◽  
Prisma Statement ◽  
Significant Burden

Abstract Background HIV and Hepatitis C Virus (HCV) infections are responsible for a significant burden of mortality and morbidity, particularly in developing countries. This study sought to determine the prevalence of HIV and Hepatitis C among injecting drug users in Afghanistan, Iran, and Pakistan. Methods This review conforms to the Preferred Reporting Guidelines for Systematic Reviews and Meta-Analysis (PRISMA) statement. Databases including PubMed, Scopus, Web of Science/Knowledge, SID.ir, and MAGIRAN were searched. Studies that were published from 2003 up to 2018 were considered for analysis. Studies were screened for inclusion in duplicate, and also, that data were narratively synthesized. Results We report on data from 79 articles. The total number of participants in studies that assessed the prevalence of HIV among injecting drug users included 68,926 participants, while those from studies that assessed HCV prevalence were 23,016 participants. Overall HIV and HCV prevalence among injecting drug users in the three selected countries were 9.1% (95% CI 6.9–12.0%) and 48.3% (95% CI 43.9–52.7%), respectively. Iran had the highest HIV prevalence of 11.0% among injectable drug users (95% CI 8.4–14.2%), while Afghanistan had the lowest HIV prevalence of 3.1% (95% CI 1.5–6.3%) among three selected countries. In Pakistan, the prevalence of HIV was 8.6% (95% CI 4.8–15.0%). Regarding HCV prevalence, Pakistan had the highest while Afghanistan had the lowest, 54.4% (95% CI 33.5–73.9%) and 37.3% (95% CI 35.2–39.4%), respectively. HCV prevalence in Iran was 47.7% (95% CI 43.4–52.0%). Conclusion Injecting drug users form a special cohort of persons at risk of HIV and Hepatitis C infections. The prevalence of HIV and Hepatitis noted from our findings is significantly high. Awareness of the grave risk of spreading HIV and Hepatitis C associated with sharing needles is recommended among this sub-group of drug users.

scholarly journals Risk factors for hepatitis C virus infection among injecting drug users in Sydney.

1994 ◽  
Vol 70 (5) ◽  
pp. 321-324 ◽  
Author(s):  
I van Beek ◽  
R Buckley ◽  
M Stewart ◽  
M MacDonald ◽  
J Kaldor
Keyword(s):  
Risk Factors ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Drug Users ◽  
Injecting Drug Users ◽  
Hepatitis C Virus Infection
Sign in / Sign up

Export Citation Format

Share Document